CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine (LT), a CD19-targeting ADC with DNA-damaging payload SG3199, demonstrated clinical activity in relapsed/refractory DLBCL (LOTIS-2: CR 24.8%, median PFS 4.9 months) [40].